| 18.42 0 (0%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.56 | 1-year : | 25.18 |
| Resists | First : | 18.45 | Second : | 21.56 |
| Pivot price | 18.41  |
|||
| Supports | First : | 18.35 | Second : | 18.29 |
| MAs | MA(5) : | 18.42 | MA(20) : | 18.4 |
| MA(100) : | 17.15 |
MA(250) : | 16.36 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 57 |
D(3) : | 60.1 |
| RSI | RSI(14): 62.3 | |||
| 52-week | High : | 21.01 | Low : | 11.09 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SLP ] has closed below upper band by 35.8%. Bollinger Bands are 97.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.48 - 18.57 | 18.57 - 18.64 |
| Low: | 18.2 - 18.31 | 18.31 - 18.4 |
| Close: | 18.26 - 18.43 | 18.43 - 18.56 |
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
Thu, 10 Sep 2026
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures - GlobeNewswire
Thu, 10 Sep 2026
First Light Asset Management LLC Raises Position in Simulations Plus, Inc. $SLP - MarketBeat
Tue, 08 Sep 2026
Groupe la Francaise Acquires Shares of 127,200 Simulations Plus, Inc. $SLP - MarketBeat
Fri, 28 Aug 2026
Simulations Plus (SLP) investors OK Altaris merger, await regulators - Stock Titan
Sun, 19 Jul 2026
Simulations Plus: The Potential Little Spread Is Not Worth The Risk For New Money, Hold - Seeking Alpha
Tue, 16 Jun 2026
Latham & Watkins Advises on Altaris Acquisition of Simulations Plus for Approximately US$375 Million - Latham & Watkins LLP
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Software - Application
|
|
| Shares Out | 20 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 16.9 (%) |
| Held by Institutions | 79.4 (%) |
| Shares Short | 2,820 (K) |
| Shares Short P.Month | 1,780 (K) |
| EPS | 0.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.88 |
| Profit Margin | 9.8 % |
| Operating Margin | 22.8 % |
| Return on Assets (ttm) | 5.4 % |
| Return on Equity (ttm) | 6.1 % |
| Qtrly Rev. Growth | 7.5 % |
| Gross Profit (p.s.) | 2.57 |
| Sales Per Share | 4.05 |
| EBITDA (p.s.) | 0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 25 (M) |
| Levered Free Cash Flow | 18 (M) |
| PE Ratio | 46.04 |
| PEG Ratio | 9.8 |
| Price to Book value | 2.67 |
| Price to Sales | 4.53 |
| Price to Cash Flow | 14.93 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|